Clovis Oncology (NASDAQ:CLVS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.33 by 6 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. JP Morgan downgrades its view on Clovis Oncology (NASDAQ:CLVS) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Overweight. JP Morgan lowers the price target from $42 per share to $15 per share on Clovis Oncology . The rating by the firm was issued on April 13, 2016.
Clovis Oncology (NASDAQ:CLVS) shares are expected to touch $19.5 in the short term. This short term price target has been shared by 6 analysts. However, the standard deviation of short term price estimate has been valued at 6.16. The target price could hit $30 on the higher end and $14 on the lower end.
Clovis Oncology (NASDAQ:CLVS) witnessed a decline in the market cap on Tuesday as its shares dropped 4.56% or 0.63 points. After the session commenced at $13.84, the stock reached the higher end at $13.958 while it hit a low of $12.78. With the volume soaring to 890,075 shares, the last trade was called at $13.18. The company has a 52-week high of $116.75. The company has a market cap of $506 million and there are 38,385,660 shares in outstanding. The 52-week low of the share price is $11.58.
Clovis Oncology, Inc. has lost 4.7% in the last five trading days and dropped 9.1% in the last 4 weeks. Clovis Oncology, Inc. has dropped 35.89% during the last 3-month period . Year-to-Date the stock performance stands at -62.34%.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.